Blood Pressure Medication Recalled after Test find Toxic Residues

Blood Pressure Medication Recalled after Test find Toxic Residues
SHARE

In the recent months several companies have recalled select lots of blood pressure medication after tests revealed that they were contaminated with a small amount of a high-risk chemical that may cause cancer.

The Food and Drug Administration as officially announced that Aurobindo Pharma USA, Inc. has decided to voluntarily recall several types of medicine. The 80 lots are comprised of Amlodipine Valsartan Tablets, Valsartan Tablets and Valsartan HCTZ tablets.

They contain trace amounts of N-nitrosodiethylamine, a substance that can be encountered in air pollution, industrial activity, drinking water and select foods. It is classified as a probable human carcinogen and can be found on several lists of banned chemicals.

The drugs mentioned in the article are used to treat blood pressure and heart failure. Patients are advised to contact their pharmacist and physician in order to receive an alternate treatment until the problem will be solved. It is not recommended to stop the treatment on the spot as the patient may face serious risks that are more dangerous than the threat posed by the affected products. No adverse symptoms have been reported until now.

Those that have recently bought one or several bottles of medication are asked to visit the FDA website and compare that lot numbers on the site with those that are written on the bottles. The company has already ceased the delivery process for the affected drugs and distributors will return them to a specified address.

Earlier in December Torrent Pharmaceuticals Limited recalled two lots of Losartan potassium tablets that were contaminated with the same chemical. In November Mylan Pharmaceutics recalled several lots of blood pressure medicine that were also contaminated with N-nitrosodiethylamine. The cause of the contamination remains unknown.

The chief of the FDA appreciated the initiative of the companies, noting that the recalls show a focus on delivering a high-quality product. It remains to be seen if other blood pressure medicine will be affected in the future.


SHARE

Share this post

Post Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.